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Background: Glioblastoma Multiforme (GBM) is one of the most aggressive primary brain tumors and is associated
with a dismal prognosis. The median survival after the primary diagnosis remains poor, even after multimodal
treatment approaches. However, a few patients have been reported to have long term survival greater than three
years. A number of studies have attempted to define factors capable of predicting long term outcomes in specific
patient groups. This article reports the outcomes of a very large group of patients diagnosed with GBM, and
analyzes specific prognostic factors known to influence survival in these patients.
Methods: We used the Surveillance, Epidemiology, and End Results (SEER) database of the US National Cancer
Institute (NCI) to investigate various patient-related and treatment- related factors that could influence the long
term survival in patients diagnosed with glioblastoma. A total of 34,664 patients aged 20 years or older with a
diagnosis of GBM during the years 1973 to 2008 were studied. Overall survival outcomes were examined with
Kaplan-Meier survival analysis and Cox hazard models.
Results: Asian/Pacific Islanders had a better survival compared to the white population (P=<0.001). Patients
diagnosed with GBM during the years 2000 to 2008 had a superior survival rate when compared with earlier
decades (P=<0 .001). Statistically significant improvements in overall survival were also found for patients who
received surgical resections, and adjuvant radiation treatment versus no radiation (P-values <0.001). Young age was
also found to be highly predictive of improved overall survival rates when separated into age groups as well as
when studied as a continuous variable.
Conclusions: Clinical pretreatment and treatment factors, including young age at diagnosis, Asian/Pacific Islander
ethnicity, recent year of diagnosis, surgical resection and the use of adjuvant radiation therapy favorably influence
survival in patients diagnosed with glioblastoma.
Trial Registration: All data were obtained from the United States Surveillance Epidemiology and End Results (SEER)
database.
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Glioblastoma remains one of the most aggressive and
lethal forms of primary malignancy of the brain. How-
ever, recent advances in the diagnostics and treatments
of glioblastoma have offered new hope for patients and
clinicians. Despite these advances in therapy, the man-
agement of glioblastoma remains a challenge. Tumor
factors such as deep infiltration of cancer cells with
microscopic extensions into surrounding normal brain
tissue, geographic location within the brain and a par-
ticular tumor’s accessibility to surgical resection may
present barriers to adequate surgical treatment. The
blood–brain barrier’s natural protection by filtration of
large chemicals also limits the penetration of chemother-
apeutic agents. Upon initial diagnosis, the standard treat-
ment consists of surgery with maximal feasible resection,
post-operative fractionated external beam radiation
(standard dose ranges between 5,940 to 6,000 cGy in 180
to 200 cGy per fraction) with concomitant and adjuvant
chemotherapy with temozolamide. The addition of temo-
zolamide has been shown to improve overall survival.
Despite this advance, the vast majority of patients still
experience disease progression within a year [1].
Currently, there is not a single standard treatment for
the recurrence of this tumor, although additional surgery,
chemotherapy and radiotherapy are used in specific clin-
ical circumstances. The types of salvage therapy are tai-
lored to each patient’s clinical situation. For example,
stereotactic radiosurgery (SRS) and novel chemotherapy
agents are increasingly used to treat the recurrent
tumors. Because of these treatment advances, outcomes
have changed dramatically for appropriately selected
patients. Previous studies have revealed that pretreat-
ment prognostic factors play a role in clinical outcomes
[2,3]. Several small studies have identified clinical, tumor
and treatment related prognostic factors that influence
outcomes [4,5]. The clinical factors of age, Karnofsky
performance status (KPS), extent of surgical resection,
post-operative radiation treatment, degree of necrosis
within the resection pathology, and the degree of en-
hancement on preoperative and postoperative MR im-
aging studies have been shown to influence survival
[6,7]. Identifying different prognostic subgroups of
patients may help tailor specific treatment regimens to
improve outcomes. The purpose of this study is to better
analyze important pretreatment and treatment factors in
the United States population associated with improve-
ments in overall survival for patients with glioblastoma.
Methods
All data were acquired from the 1997 to 2008 limited
use databases of the Surveillance, Epidemiology, and End
Results (SEER) Program of the US National Cancer Insti-
tute (NCI), which contains data from geographicallyspecified United States locations that span a population
of approximately 30 million people. Registry data are
submitted without personal identifiers; therefore, patient
informed consent and ethics committee approval were
not required to perform this analysis.
We examined 34,664 patients aged 20 years or older
with a diagnosis of glioblastoma multiforme (GBM) be-
tween 1973 and 2008. The patients were grouped by race
(White, Black, Asian/Pacific Islander, American Indian/
Alaska Native, Other, Unknown), diagnosis year (1973 to
1979, 1980 to 1989, 1990 to 1999, 2000 to 2008), radi-
ation treatment (Yes, No, Unknown), extent of surgery
(Surgical Resection, No Cancer Directed Resection, Un-
known) and age at diagnosis (<50, >/= 50). Patients
younger than 50 years were further sub-grouped into 10-
year age-bands. Chemotherapy as a prognostic variable
was not included since details regarding this were not
available in the SEER database. Numbers of patients in
the racial groups, diagnosis year groups and age groups
are shown in Table 1 and numbers of patients in the ra-
diation treatment groups and extent of surgery groups
are shown in Table 2. Similarly, the distributions of
patients younger than 50 years into 10-year age-bands
for these same groupings are shown in Tables 3 and 4.
Survival curves were estimated using the Kaplan-Meier
method and used to compare racial groups, diagnosis
year groups, radiation treatment groups, extent of sur-
gery groups and age groups. Andersen 95% confidence
intervals for the median survival time of the groups were
constructed. Peto’s log-rank tests were employed to de-
termine if there is statistical evidence of differences be-
tween the survival curves of the groups. Exact
conditional maximum likelihood estimates were used to
calculate the groups’ hazard ratios and Fisher 95% confi-
dence intervals were constructed for significance testing
between the groups’ hazard ratios. To look at group dif-
ferences between survival rates specifically at one-year,
two-years, and five-years, absolute survival rates were
calculated with 95% confidence intervals using a max-
imum likelihood solution from an asymptotic distribu-
tion by the transformation of survivorship (lx). Finally,
the Cox proportional hazard model was used in a multi-
variate analysis of the racial, diagnosis year, radiation
treatment, and extent of surgery categorical variables as
well age as a continuous variable. Statistical significance
was set at a p value <0.05. All statistical analyses utilized
Stats Direct Version 2.5.7 (Stats Direct Ltd., Altrincham,
UK) and Sigma Plot Version 11.0 (SYSTAT Software,
Inc., San Jose, CA, USA).
Results
Kaplan-Meier survival curves for racial groups are
depicted in Figure 1. There was a significant difference
in survival of the Asian/Pacific Islander group as
Table 1 Numbers of patients with GBM by racial groups,
diagnosis year groups, and age groups
Age Groups
<50 >/= 50 Total
Racial Groups Diagnosis
Year Groups
White 1973 to 1979 542 2,149 2,691
1980 to 1989 677 3,587 4,264
1990 to 1999 1,226 6,307 7,533
2000 to 2008 2,634 14,698 17,332
White Total 5,079 26,741 31,820
Black 1973 to 1979 26 79 105
1980 to 1989 59 112 171
1990 to 1999 83 287 370
2000 to 2008 179 701 880
Black Total 347 1,179 1,526
Asian/
Pacific Islander
1973 to 1979 14 24 38
1980 to 1989 23 64 87
1990 to 1999 80 248 328






1973 to 1979 – – –
1980 to 1989 – 2 2
1990 to 1999 6 18 24




Unknown 1973 to 1979 – 2 2
1980 to 1989 2 2 4
1990 to 1999 3 6 9
2000 to 2008 5 19 24
Unknown Total 10 29 39
Other 1973 to 1979 – – –
1980 to 1989 – – –
1990 to 1999 – 1 1
2000 to 2008 2 12 14
Other Total 2 13 15
All Races 1973 to 1979 582 2,254 2,836
1980 to 1989 761 3,767 4,528
1990 to 1999 1,398 6,867 8,265
2000 to 2008 2,991 16,044 19,035
All Races Total 5,732 28,932 34,664
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evidence of significantly improved survival for patients
diagnosed in 2000 to 2008 as compared to earlier yearsas depicted in Figure 2. Surgical resection and the use of
adjuvant radiation treatment were associated with signifi-
cantly improved survival outcomes as shown in Figures 3
and 4. Likewise, Figure 4 depicts improved survival for
patients undergoing surgical resection. Figures 5 and 6
show significantly improved survival for patients diag-
nosed at younger ages.
Univariate median survival confidence interval and
hazard ratio confidence intervals are included in Table 5.
For each category, a reference group was selected
(Race =White, Diagnosis year = 1973 to 1979, Radiation
treatment = Yes, Extent of Surgery = surgical resection,
Age =/<50 years, Ten-year age-band = 20 to 29 years)
against which the other group’s hazard ratios were
tested. The hazard ratios of the Asian/Pacific Islander
and Other racial groups were found to be statistically
superior to the White group (P< 0.001 and P = 0.009
respectively). All three of the later diagnosis year groups’
hazard ratios were found to be improved as compared to
the reference group of 1973 to 1979 (P=0.005 for both the
1980 to 1989 and 1990 to 1999 groups, P< 0.001 for the
2000 to 2008 group). Both the “No radiation” and “Un-
known radiation” hazard ratios were determined to be in-
ferior as compared to the “Yes radiation” reference group
(P< 0.001 in both cases). The patients in the “No Cancer
Directed Resection” group were found to have less favor-
able outcomes as compared to the Surgical Resection
reference group (P< 0.001). Finally, all three variations of
reviewing the impact of age indicated that patients diag-
nosed at older ages had less favorable hazard experiences
(P< 0.001). Univariate 1-, 2-, and 5-year absolute survival
rates for groups were also examined and are shown in
Table 6. Significance was declared for a value< 0.025. Sur-
vival rate comparisons yielded broadly similar results as
the univariate hazard ratio tests.
The multivariate analysis hazard ratio estimates and
confidence intervals are included in Table 7. The multi-
variate analysis utilized the same reference groups as the
univariate analyses against which the other group’s haz-
ard ratios were tested. Similar to the univariate analysis,
the Asian/Pacific Islander and Other racial group’s haz-
ard ratios were significantly better than the reference
group of White patients (P< 0.001 and P= 0.002,
respectively). Likewise, we found similar results regard-
ing the diagnosis year groups in that, all three later diag-
nosis groupings (1980 to 1989, 1990 to 1999, 2000 to
2008) had significantly superior survival as compared to
the reference 1973 to 1979 group (P< 0.001 in all three
cases). In both the radiation and extent of surgery cat-
egorical variables, the multivariate analysis found signifi-
cantly better outcomes for the reference group compared to
others (P< 0.001 in all cases). In the multivariate analysis
age was also examined as a continuous variable and was
found to significantly impact overall survival (P< 0.001)
Table 2 Numbers of patients with GBM by radiation treatment groups, extent of surgery groups, and age groups
Age Groups
<50 >=50 Total
Radiation Groups Extent of Surgery Groups
Yes Surgical Resection 3,838 14,216 18,054
No Cancer Directed Resection 548 3,764 4,312
Unknown 159 861 1,020
Yes Total 4,545 18,841 23,386
No Surgical Resection 654 4,498 5,152
No Cancer Directed Resection 297 3,788 4,085
Unknown 92 845 937
No Total 1,043 9,131 10,174
Unknown Surgical Resection 91 505 596
No Cancer Directed Resection 19 195 214
Unknown 34 260 294
Unknown Total 144 960 1,104
All Radiation Groups Surgical Resection 4,583 19,219 23,802
No Cancer Directed Resection 864 7,747 8,611
Unknown 285 1,966 2,251
All Radiation Groups Total 5,732 28,932 34,664
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1.038). Thus, younger age was associated with an improved
survival rate.
Discussion
The median survival after the primary diagnosis in
patients with GBM is 12 to 16 months [8]. The patients
who survive more than three years after the diagnosis
are described as long term survivors [9]. It is not clear as
to why a small subgroup of patients have significantly
better outcomes and this could be related to clinical-,
tumor- or treatment-related factors or other unknown
variables. We found that the clinical factors of age less
than 50 years, Asian race, surgical resection of the tumor,
adjuvant radiation treatment and recent diagnosis year
from 2000 to 2008 correlated with improved survival.
Most authors agree that young age at presentation is a
predictor of long term survival in patients with glioblast-
oma [3,10]. In our study, when compared to the
“<50 years” group, the “>50 years” group showed a sig-
nificant decrease in survival (hazard ratio 2.22; 95% CI,
2.17 to 2.33; P=<0.001). When compared to “20 to 29”
group, the “30 to 39 year” group (hazard ratio 1.23; 95%
CI, 1.10 to 1.39; P=<0.001) and “40 to 49 year” group
(hazard ratio 1.85; 95% CI, 1.67 to 2.04; P=<0.001)
showed statistically significant decreased survival. Also,
for every year increase in patient age, there was a signifi-
cant decrease in survival (hazard ratio 1.037; 95% CI,
1.036 to 1.038; P=<0.001), which is a unique finding in
our study. Our study results are consistent with severalstudies done in the past. In 1993, Chandler et al. esti-
mated a mean age of 39.2 years in a group of 22 long
term survivors with a median duration of survival of
9.4 years [11]. Scott et al. reported that 2.2% (n = 15) of a
series of 689 glioblastoma patients survived more than
three years, and had a mean age of 43.5 +/− 3.3 years
[12]. Sneed et al. conducted a retrospective review to
study the influence of age on the survival of patients with
glioblastoma treated with radiotherapy and a brachyther-
apy boost. The univariate and multivariate analyses
showed age as the most significant factor influencing
survival (P=<.0005) and patients younger than 29.9 years
had the highest probability of long term survival [13].
Studies by Ohgaki et al. reported that patients diagnosed
with secondary GBM (GBMs arising from lower grade
CNS tumors) survived significantly longer than those
with primary GBM. However, they correlated this finding
to the younger age of cases with secondary GBMs than
as a reflection of different biologic behavior [14]. Many
studies have emphasized the importance of age as a fac-
tor influencing survival in patients with glioblastoma,
but a unique finding in our study was that for this popu-
lation analysis there was a survival advantage for younger
age by 10-year increments and also when examining age
as a continuous variable.
Race as a factor in affecting the survival of patients with
GBM has been studied in the past. The most striking find-
ing in our study was that the Asian/Pacific Islanders had a
significantly superior survival (hazard ratio 0.83; 95% CI,
0.78 to 0.79; P=<0.001) when compared to the White
Table 3 Numbers of patients with GBM aged <50 by racial




20 to 29 30 to 39 40 to 49 Total
White 1973 to 1979 90 134 318 542
1980 to 1989 86 190 401 677
1990 to 1999 117 312 797 1,226
2000 to 2008 231 551 1,852 2,634
White Total 524 1,187 3,368 5,079
Black 1973 to 1979 7 8 11 26
1980 to 1989 6 18 35 59
1990 to 1999 9 19 55 83
2000 to 2008 20 29 130 179
Black Total 42 74 231 347
Asian/
Pacific Islander
1973 to 1979 4 3 7 14
1980 to 1989 1 7 15 23
1990 to 1999 10 28 42 80
2000 to 2008 20 33 101 154
Asian/Pacific
Islander Total
35 71 165 271
American Indian/
Alaska Native
1973 to 1979 – – – –
1980 to 1989 – – –
1990 to 1999 3 3 6
2000 to 2008 2 3 12 17
American Indian/
Alaska Native Total
2 6 15 23
Unknown 1973 to 1979 – – – –
1980 to 1989 – – 2 2
1990 to 1999 1 1 1 3
2000 to 2008 – 3 2 5
Unknown Total 1 4 5 10
Other 1973 to 1979 – – – –
1980 to 1989 – – – –
1990 to 1999 – – – –
2000 to 2008 – – 2 2
Other Total – – 2 2
All Races 1973 to 1979 101 145 336 582
1980 to 1989 93 215 453 761
1990 to 1999 137 363 898 1,398
2000 to 2008 273 619 2,099 2,991
All Races Total 604 1,342 3,786 5,732
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Barnholtz-Sloan et al. [2]. Between 1991and 1999, they
studied 1,530 patients in the SEER database diagnosed
with glioblastoma aged greater than 65 years of age with
the intention to analyze racial differences in survival. Asignificant racial difference in survival was seen in the
Asian population when compared to white, black and
other populations. Robertson et al. [15] studied the inci-
dence of glioblastoma, astrocytoma and oligodendroglioma
in the white and black population in the Memphis Statis-
tical Metropolitan area during the 1984 to 1994 period.
This study did not include the Asian race, but confirmed
that there were no significant differences in survival be-
tween the white and black populations despite disparity in
the incidence rates. Our results confirm that racial differ-
ences in survival exist in patients diagnosed with glioblast-
oma, with the Asian race having increased survival when
compared to other races. The reasons for this are not
clearly defined. Small studies have suggested that genetic
and molecular differences may play a role. There may be a
higher incidence of primary glioblastomas overexpressing
p 53 (Protein 53 or tumor protein 53) and PDGFR-alpha
(Platelet Derived Growth Factor Receptor) similar to sec-
ondary glioblastomas in Asians [16]. However, other un-
known molecular and biologic factors may play a role and
this needs to be further investigated.
The management of glioblastoma has progressively
changed and evolved over the course of the last two dec-
ades with new developments in technology to help with
diagnosis, novel radiation techniques and advances in sur-
gical procedures [17]. Not surprisingly, several studies have
shown an improvement in outcomes over the last decade
[10,18,19]. An interesting finding in our study was that the
patients who were diagnosed with glioblastoma during the
years 2000 to 2008 had a significantly improved survival
(hazard ratio 0.78; 95% CI, 0.74 to 0.81; P=<0.001) when
compared to other groups. The second group (1980 to
1989) with a hazard ratio of 0.93 (95% CI, 0.88 to 0.98;
P=0.005) and the third group (1990 to 1999) with a haz-
ard ratio of 0.93 (95% CI, 0.89 to 0.98; P=0.005) also
showed improved survival when compared to the refer-
ence group. Our study shows a gradual increase in median
survival in patients diagnosed with glioblastoma from the
year 1973 to the year 2008. This could be related to the
ever-changing patterns of care, and improvement in
supportive care as well as improved radiation and surgi-
cal treatments being administered to these patients.
Koshy et al. [19] recently reported a study involving
patients diagnosed with GBM who underwent surgery
and post-operative RT. These patients were selected
from the Surveillance, Epidemiology and End Results
database and grouped into time periods: 2000 to 2001, 2002
to 2003, 2004 and 2005 to 2006 based on year of diagnosis.
They concluded that patients diagnosed in 2005 to 2006
had significantly improved survival when compared to
patients diagnosed in 2000 to 2001 (HR=0.648, 95% CI
0.604 to 0.696). This finding is consistent with our findings.
With the advent of novel chemotherapeutic drugs,
improved radiation techniques (including 3-D conformation
Table 4 Numbers of patients with GBM aged <50 by radiation treatment groups, extent of surgery groups, and 10-year
age-bands
10-Year Age-Bands
20 to 29 30 to 39 40 to 49 Total
Radiation Groups Extent of Surgery Groups
Yes Surgical Resection 378 911 2,549 18,054
No Cancer Directed Resection 64 111 373 4,312
Unknown 22 41 96 1,020
Yes Total 464 1,063 3,018 23,386
No Surgical Resection 78 152 424 5,152
No Cancer Directed Resection 34 64 199 4,085
Unknown 12 26 54 937
No Total 124 242 677 10,174
Unknown Surgical Resection 6 28 57 596
No Cancer Directed Resection 4 3 12 214
Unknown 6 6 22 294
Unknown Total 16 37 91 1,104
All Radiation Groups Surgical Resection 462 1,091 3,030 4,583
No Cancer Directed Resection 102 178 584 864
Unknown 40 73 172 285
All Radiation Groups Total 604 1,342 3,786 5,732
Thumma et al. World Journal of Surgical Oncology 2012, 10:75 Page 6 of 12
http://www.wjso.com/content/10/1/75radiation, intensity modulated radiotherapy (IMRT), and
stereotactic radiosurgery (SRS)), advanced surgical techni-
ques, and a better understanding of molecular biology, the
median survival could be expected to increase further in the
coming years. In fact, several recent studies have reported
an increased number of long term survivors [20-26]. Scoc-
cianti et al. studied 1,059 patients treated in 18 radiotherapy
centers in Italy between 2002 and 2007 and clinical, patho-
logical, therapeutic and survival data regarding these
patients were collected and retrospectively reviewed. They
reported a significant difference in survival in these patients
compared to patients treated between 1997 and 2001 and
attributed it to a significantly increased frequency of MRI
imaging, increasing use of surgery as opposed to biopsy and
use of 3-D conformal radiotherapy and temozolamide [27].
Surgical resection done after the primary diagnosis can
prolong the survival, allow more comprehensive histo-
logical diagnosis and can provide relief from neurologic
deficits related to the mass effect. Our study results are
consistent with results of other studies [5,28]. When
compared to the “Surgical Resection” group, the “No
Cancer Related Resection” group showed a significantly
decreased survival. This marked difference in survival
emphasizes the importance of surgical resection, and
also how the extent of surgical resection plays a role in
prolonging the survival in patients with glioblastoma.
Filippini et al. reported a significant difference in survival
in patients who had undergone surgical resection vspatients who underwent only biopsy [29]. The hazard
ratio for death in patients who had undergone surgical
resection versus those who had undergone biopsy only
was 0.55 (95% CI, 0.42 to 0.72; P=<0.001), a 45% rela-
tive reduction in the risk of death or an eight-month in-
crease in median survival time. Gross total resection/
extensive resection of the tumor at the time of initial
diagnosis was associated with statistically significant
increased survival when compared to sub-total resec-
tion/partial resection [29,30]. Patients older than 65 to
75 years of age, unlike younger patients, are often not
offered aggressive surgery because of their age, asso-
ciated comorbidities and the potential inability to toler-
ate surgery. In a recent study reported by Oszvald et al.,
the overall survival of older patients aged greater than
65 years (9.1 ± 11.6 months) was significantly lower than
that of younger patients (14.9 ± 16.7 months; P= 0.0001)
[31]. However, age was a negative prognostic factor in
patients undergoing biopsy (4.0 ± 7.1 vs 7.9 ± 8.7 months;
P= 0.007), but not in patients undergoing tumor resec-
tion (13.0 ± 8.5 vs 13.3 ± 14.5 months; P= 0.86). Survival
of older patients undergoing complete tumor resection
was 17.7 ± 8.1 months and compared favorably with
younger patients emphasizing the importance of surgery.
Radiation therapy remains the post-operative backbone
in the management of patients with glioblastoma. Our
study confirms the importance of radiation treatment in
prolonging the survival of patients with glioblastoma.
Figure 1 Survival curves of patients with GBM by racial group.
Figure 3 Survival curves of patients with GBM by radiation
treatment groups.
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CI, 3.33 to 3.45; P=/<0.001) and the “Unknown radi-
ation” group (hazard ratio 2.50; 95% CI, 2.33 to 2.70;
P=/<0.001) showed a marked decreased survival whenFigure 2 Survival curves of patients with GBM by diagnosis
year groups.compared to the “Yes radiation” group of patients. Stud-
ies by Filippini et al. have shown that radiotherapy in
glioblastoma patients can increase survival, with a one-Figure 4 Survival curves of patients with GBM by extent of
surgery groups.
Figure 5 Survival curves of patients with GBM by age groups.
Table 5 Univariate median survival estimates (months)
and hazard ratios of patients with GBM by racial groups,
diagnosis year groups, and age groups
Median Survival Hazard Ratio
n 95% CI Estimate 95% CI P-value**
Racial Groups
White* 31,820 6±0.11 reference
Black 1,526 6±0.61 0.95 0.89 to 1.00 0.066
Asian/Pacific
Islander
1,177 8±0.67 0.83 0.78 to 0.89 <0.001
American Indian/
Alaskan Native
87 6±2.03 0.86 0.68 to 1.10 0.237
Unknown 39 9± 6.10 0.59 0.37 to 0.88 0.009
Other 15 6 ± 19.91 0.75 0.35 to 1.43 0.467
Diagnosis Year Groups
1973 to 1979* 2,836 5 ± 0.35 reference
1980 to 1989 4,528 6 ± 0.28 0.93 0.88 to 0.98 0.005
1990 to 1999 8,265 6 ± 0.20 0.93 0.89 to 0.98 0.005
2000 to 2008 19,035 7 ± 0.18 0.78 0.74 to 0.81 <0.001
Radiation Treatment Groups
Yes* 23,386 9 ± 0.13 reference
No 10,174 2 ± 0.06 3.45 3.33 to 3.45 <0.001
Unknown 1,104 3 ± 0.26 2.50 2.33 to 2.70 <0.001
Extent of Surgery Groups
Surgical Resection* 23,802 9 ± 0.14 reference
No Cancer 8,611 3 ± 0.09 2.38 2.33 to 2.44 <0.001
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reduction in relative risk of dying [29]. Substantial
research is underway to develop methods for enhancingFigure 6 Survival curves of patients with GBM < 50 years old
by 10-year age bands.
Directed Resection
Unknown 2,251 3 ± 0.18 0.96 0.93 to 1.00 0.126
Age (Continuous Variable)
Age 34,664 1.037 1.036 to 1.038 <0.001
Age Groups
<50* 5,732 14±0.37 reference
>=50 28,932 5±0.10 2.22 2.17 to 2.33 <0.001
Ten-Year Age-Bands (<50 only)
20 to 29* 604 20±2.37 reference
30 to 39 1,342 16±1.05 1.23 1.10 to 1.39 <0.001
40 to 49 3,786 12±0.39 1.85 1.67 to 2.04 <0.001
* Reference group against which other groups’ survival experience are
compared.
** P-value for test if groups’ survival experience is same as reference groups.the radio-sensitivity of GBM as most patients relapse
after initial response. Tumor tissue hypoxia has been
reported as an important mechanism involving tumor
resistance to radiation, and using substances that can in-
crease tumor sensitivity to radiation (radiosensitizers) is
being recommended [32]. In the landmark randomized
study, Stupp et al. reported that delivery of temozola-
mide during radiotherapy increased survival, suggesting
that this DNA alkylating agent can increase survival by
enhancing radiosensitivity of GBM cells. This study
Table 6 Univariate 1-, 2-, and 5-year absolute survival rates of patients with GBM by racial groups, diagnosis year
groups, radiation treatment groups, extent of surgery groups, and age groups
1-year 95% CI 2-year 95% CI 5-year 95% CI
Racial Groups
White* 30.54 30.03–31.05 10.11 9.76–10.46 3.25 3.02–3.48
Black 32.42 30.06–34.80 12.10 10.44–13.88 3.31 2.34–4.55
Asian/Pacific Islander 36.79 33.99–39.59 ** 15.17 13.04–17.44 ** 5.30 3.89–7.02 **
Am. Indian/Alaskan 29.41 20.16–39.26 11.51 5.71–19.54 8.12 3.22–15.97
Unknown 47.06 29.83–62.52 32.20 15.30–50.09 ** 18.40 4.95–38.54 **
Other 53.85 24.77–75.99 29.91 6.78–58.20 insufficient data
Diagnosis Year Groups
1973 to 1979* 24.79 23.21–26.39 6.86 5.97–7.83 2.30 1.79–2.90
1980 to 1989 26.39 25.12–27.69 7.36 6.62–8.14 2.41 1.99–2.89
1990 to 1999 26.77 25.82–27.73 7.11 6.56–7.67 2.18 1.88–2.52
2000 to 2008 34.75 34.06–35.44 ** 13.45 12.93–13.98 ** 4.37 3.99–4.77 **
Radiation Treatment Groups
Yes* 41.12 40.48–41.75 13.68 13.22–14.15 4.13 3.83–4.44
No 9.25 8.70–9.83 ** 3.50 3.13–3.89 ** 1.74 1.46–2.05 **
Unknown 15.69 13.60–17.91 ** 5.43 4.15–6.95 ** 2.10 1.28–3.26 **
Extent of Surgery Groups
Surgical Resection* 39.21 38.58–39.84 13.39 12.93–13.85 4.23 3.94–4.55
No Cancer Directed Resection 12.78 12.08–13.50 ** 3.92 3.49–4.37 ** 1.44 1.16–1.76 **
Unknown 12.83 11.48–14.24 ** 3.78 3.05–4.63 ** 1.35 0.93–1.90 **
Age Groups
<50* 58.32 57.01–59.60 26.56 25.37–27.76 11.12 10.22–12.05
>= 50 25.46 24.95–25.97 ** 7.14 6.83–7.46 ** 1.67 1.49–1.87 **
Ten-Year Age-Bands (<50 only)
20 to 29* 68.17 64.24–71.77 44.90 40.74–48.96 23.09 19.48–26.89
30 to 39 65.31 62.66–67.83 35.55 32.89–38.21 ** 16.73 14.60–18.98 **
40 to 49 54.26 52.63–55.85 ** 20.38 19.05–21.75 ** 7.09 6.19–8.07 **
* Reference group against which other groups’ survival experience are compared.
** Statistically significant result (P< 0.025) comparing whether groups’ survival rate is the same as reference group.
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temozolamide to be 27.2% at two years, 16.0% at three
years, 12.1% at four years and 9.8% at five years [33].
SRS is being increasingly used to treat recurrent tumors
because it can target any area of the brain with extreme
accuracy, thereby minimizing the effect of radiation on
the adjacent brain tissue and the critical structures
nearby. SRS can be used multiple times in select situa-
tions and also can be used to treat multiple sites of
recurrences in the same treatment setting. Recent studies
have shown that re-irradiation with stereotactic radio-
surgery for recurrent glioblastoma is a very effective and
feasible method of improving survival [34,35].
The complex molecular and biologic factors leading to
the development of glioblastomas are beginning to be
unraveled and our understanding of molecular patho-
genesis has increased significantly in the last twodecades. Glioblastomas are a heterogeneous group of
tumors and likely arise as a result of multiple genetic
alterations, including activation of oncogenes, inactiva-
tion of tumor suppressor genes or deregulation of DNA
repair genes or other mechanisms [36]. Abnormal ex-
pression of tumor suppressor genes tp 53 or p 53 (tumor
protein 53), PTEN (phosphatase and tensin homolog)
and mdm2 (murine double minute oncogene) an im-
portant negative regulator of p53 have been implicated
in the pathogenesis of GBM. Karyotyping has revealed
multiple other abnormalities with significant differences
between primary and secondary glioblastomas (GBM
that arises as a result of transformation of lower grade
gliomas). Trisomy 7, monosomy 10, allelic loss of 17p,
epidermal growth factor receptor gene (EGFR) amplifi-
cation are some of the other abnormalities that have
been identified. TP 53 mutations are more frequent in
Table 7 Multivariate hazard ratios, confidence intervals,
and P-values of patients with GBM by racial groups,
diagnosis year groups, and age
Hazard Ratio
Estimate 95% CI P value**
Racial Groups
White* reference
Black 0.97 0.91 to 1.02 0.238
Asian/Pacific Islander 0.89 0.83 to 0.95 <0.001
American Indian/Alaska Native 0.87 0.69 to 1.10 0.230
Unknown 0.51 0.33 to 0.78 0.002
Other 0.91 0.49 to 1.69 0.764
Diagnosis Year Groups
1973 to 1979* reference
1980 to 1989 0.88 0.87 to 0.89 <0.001
1990 to 1999 0.80 0.78 to 0.81 <0.001
2000 to 2008 0.65 0.62 to 0.68 <0.001
Radiation Treatment Groups
Yes* reference
No 2.00 1.95 to 2.06 <0.001
Unknown 1.59 1.48 to 1.70 <0.001
Extent of Surgery Groups
Surgical Resection* reference
No Cancer Directed Resection 1.64 1.59 to 1.69 <0.001
Unknown 1.27 1.20 to 1.34 <0.001
Age (Continuous Variable)
Age 1.031 1.030 to 1.032 <0.001
* Reference group against which other groups’ survival experience are
compared.
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EGFR gene amplification [37]. Secondary GBMs are
associated with better outcomes compared to primary
GBM [14]. Recently, other biologic factors have been
reported that have been associated with favorable out-
comes. Sano et al. [38] noted a statistically significant
improved prognosis for patients with glioblastoma mul-
tiforme whose tumors expressed high levels of PTEN
messenger RNA. Burton et al. analyzed tumors from 41
patients with GBM that survived 3 years or longer and
compared them with 48 patients that survived less than
1.5 years for p53 aberrations (expression/mutation), epi-
dermal growth factor receptor overexpression, mdm2
overexpression and proliferation index. Long-term survi-
vors were significantly more likely to overexpress p53
(although a difference in p53 mutation rate was not
observed) and significantly less likely to exhibit mdm2
overexpression, and had a significantly lower proliferation
rate compared with typical GBM survivors [4]. Deletion of
NFKBIA (encoding nuclear factor of κ-light polypeptidegene enhancer in B-cells inhibitor-α), an inhibitor of the
EGFR-signaling pathway, promotes tumorigenesis in glio-
blastomas that do not have alterations of EGFR and is
associated with a poor prognosis [39].
There is growing evidence that expression of O (6)-
methylguanine-DNA methyltransferase (MGMT), a DNA
repair enzyme that causes resistance to alkylating agents
plays an important role in the pathogeneisis of glioma.
Promoter methylation of MGMT leads to epigenetic silen-
cing of the MGMTand this compromises DNA repair and
has been associated with improved outcomes in patients
with glioblastoma who receive alkylating agents. There is
also evidence that MGMT hypermethylation and low or
absent expression are frequent in oligodendroglial tumors
and likely contribute to the chemosensitivity and improved
outcomes of these tumors. Wiencke et al. reported that
younger age was associated with increased incidence of TP
53 mutation and it is possible that this may be directly or
indirectly related to better outcomes related to young age
[40]. They also reported similar findings of increased TP
53 mutations in African Americans and Asians compared
to Whites. Several studies have found an inverse relation-
ship between glioma risk and atopy or allergy history and
this is an area of ongoing research [41]. It is possible that
some of these and other unknown molecular differences
are associated with improved outcomes related to age, race
and treatment, and future research should look into the
molecular heterogeneity between different prognostic sub-
groups of patients.
Conclusions
In conclusion, to our knowledge this is the largest reported
population analysis in the world literature of patient survival
outcomes with glioblastoma. For a patient with glioblast-
oma, variables predicting longer survival include younger
age (<50 years), race of the patient (Asian race being favor-
able), surgical excision of the tumor (gross total resection
preferred), and adjuvant radiation treatment. Also, addition
of temozolamide to local treatment improves survival based
on randomized studies. Our study did not include assess-
ment of chemotherapy as a prognostic variable since details
regarding this were not available in the SEER database.
Future research should explore the biologic differences
between different prognostic subgroups of patients. With
this near universally fatal disease, any small breakthrough
will have a significant impact on survival and provide hope
to the thousands of patients who receive this diagnosis an-
nually. Also, the continued individualization of treatment
for each unique patient’s situation will allow for improve-
ments in survival as well as quality of life.
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